EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Biotechnology

Healthcare
$2.99 +1.98%

+$0.26 today

Market cap
$250.69M
Beta
1.75
P/E (TTM)
-4.2
EPS (TTM)
-$3.16
52W Low $7.94High $19.11

Volume 2.75M

Average 0.95M

EYPT Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT

Deferred Tax Liabilities · Q1 FY2026 · quarter ended Mar 2026

Deferred tax liabilities remains negative

Q1 FY2026 deferred tax liabilities was $0, compared with $0 a year earlier.

Context

  • Deferred tax liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred tax liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Tax Liabilities vs competitors

How EYPT compares with its peers on the latest reported figures

  • EYPT's Mar 2026 deferred tax liabilities of $0 is the highest of the 11 companies compared; the peer median is $0.
  • Deferred tax liabilities amounts to 0.0% of total assets for EYPT, versus a peer median of 0.0%.
EYPT Competitors Peer median
Deferred Tax Liabilities for EYPT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
KODKodiak Sciences Inc.Sep 2026$0 ——0.0%
TNGXTango Therapeutics, Inc.Sep 2026$0 ——0.0%
NRIXNurix Therapeutics, Inc.Aug 2026$0 ——0.0%
SEPNSepterna, Inc.Sep 2026$0 ——0.0%
BCAXBicara Therapeutics Inc. Common StockMar 2026$0 ——0.0%
SVRASavara Inc.Mar 2026$0 ——0.0%
KURAKura Oncology, Inc.Mar 2026$0 ——0.0%
PRMEPrime Medicine, Inc.Mar 2026$0 ——0.0%
RZLTRezolute, Inc.Mar 2026$0 ——0.0%
PROKProKidney Corp.Mar 2026$0 ——0.0%
Peer median (excluding EYPT) $0——0.0%

Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents178.59M95.63M281.26M99.7M101.82M
Short-term Investments32.97M48.93M49.79M271.21M204.27M
Net Receivables18.35M15.5M805K607K651K
Inventory3.62M2.89M3.91M2.31M1.81M
Other Current Assets517K782K1.01M1.41M20.11M
Total Current Assets237.75M172.81M344.8M383.31M328.66M
Property, Plant & Equipment (Net)2.73M7.4M10.23M29.18M20.22M
Goodwill00000
Intangible Assets22.75M0000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets150K150K150K5.98M15.12M
Total Non-current Assets25.63M7.55M10.38M35.16M35.34M
Total Assets263.37M180.36M355.18M418.47M364M
Account Payables7.39M5.92M6.5M11.72M10.49M
Short-term Debt010.48M000
Tax Payables00000
Deferred Revenue1.07M1.21M38.59M17.78M0
Other Current Liabilities7.32M9.52M13.28M13.27M16.67M
Total Current Liabilities23.66M34.54M63.26M49.05M37.02M
Long-term Debt36.56M29.31M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)14.56M13.56M20.69M10.85M0
Other Non-current Liabilities2.35M600K0205K87K
Total Non-current Liabilities55.33M49.45M25.6M32.92M20.86M
Total Liabilities78.99M83.99M88.86M81.96M57.88M
Common Stock34K34K49K68K83K
Retained Earnings(569.1M)(671.35M)(742.15M)(873.02M)(1.1B)
Accumulated OCI841K786K864K1.03M961K
Other Stockholders Equity00000
Minority Interest00000
Total Equity184.38M96.37M266.32M336.5M306.11M
Total Debt39.2M46.35M4.91M21.86M20.77M
Net Debt(139.39M)(49.29M)(276.36M)(77.85M)(81.05M)

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Intrinsic Alpha fair value

Locked

Current Price

$2.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.